Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 5 studies | 32% ± 11% | |
epithelial cell of proximal tubule | 4 studies | 22% ± 4% | |
glutamatergic neuron | 4 studies | 36% ± 6% | |
renal principal cell | 4 studies | 47% ± 16% | |
type B pancreatic cell | 3 studies | 36% ± 11% | |
epithelial cell | 3 studies | 41% ± 21% | |
basal cell | 3 studies | 21% ± 5% | |
interneuron | 3 studies | 32% ± 13% | |
neuron | 3 studies | 19% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2154.84 | 244 / 245 | 100% | 132.03 | 502 / 502 |
thymus | 100% | 1315.01 | 653 / 653 | 88% | 34.39 | 532 / 605 |
kidney | 100% | 1421.73 | 89 / 89 | 67% | 18.09 | 606 / 901 |
brain | 88% | 298.01 | 2322 / 2642 | 79% | 4.82 | 559 / 705 |
esophagus | 88% | 325.73 | 1276 / 1445 | 75% | 6.27 | 137 / 183 |
bladder | 86% | 179.57 | 18 / 21 | 75% | 8.17 | 379 / 504 |
uterus | 79% | 115.02 | 134 / 170 | 82% | 11.14 | 375 / 459 |
lung | 82% | 165.45 | 476 / 578 | 73% | 7.27 | 842 / 1155 |
intestine | 64% | 157.99 | 621 / 966 | 69% | 4.56 | 362 / 527 |
ovary | 83% | 792.62 | 149 / 180 | 49% | 3.21 | 210 / 430 |
adrenal gland | 72% | 140.06 | 185 / 258 | 58% | 5.84 | 133 / 230 |
skin | 57% | 81.88 | 1033 / 1809 | 67% | 5.70 | 314 / 472 |
stomach | 59% | 97.99 | 211 / 359 | 53% | 4.05 | 152 / 286 |
breast | 47% | 60.56 | 214 / 459 | 40% | 2.46 | 451 / 1118 |
muscle | 87% | 913.15 | 696 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 82% | 8.07 | 37 / 45 |
pancreas | 33% | 42.78 | 108 / 328 | 47% | 4.51 | 84 / 178 |
blood vessel | 77% | 124.73 | 1026 / 1335 | 0% | 0 | 0 / 0 |
liver | 23% | 57.03 | 52 / 226 | 25% | 3.28 | 103 / 406 |
adipose | 45% | 69.16 | 542 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 25% | 1.13 | 20 / 80 |
heart | 19% | 43.38 | 162 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 19% | 27.76 | 174 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 14% | 0.58 | 4 / 29 |
spleen | 12% | 12.16 | 29 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006941 | Biological process | striated muscle contraction |
GO_0001657 | Biological process | ureteric bud development |
GO_0071650 | Biological process | negative regulation of chemokine (C-C motif) ligand 5 production |
GO_2000774 | Biological process | positive regulation of cellular senescence |
GO_0045087 | Biological process | innate immune response |
GO_0002829 | Biological process | negative regulation of type 2 immune response |
GO_1903426 | Biological process | regulation of reactive oxygen species biosynthetic process |
GO_0002250 | Biological process | adaptive immune response |
GO_0071644 | Biological process | negative regulation of chemokine (C-C motif) ligand 4 production |
GO_0019547 | Biological process | arginine catabolic process to ornithine |
GO_0000050 | Biological process | urea cycle |
GO_0032696 | Biological process | negative regulation of interleukin-13 production |
GO_0032651 | Biological process | regulation of interleukin-1 beta production |
GO_0006809 | Biological process | nitric oxide biosynthetic process |
GO_1905403 | Biological process | negative regulation of activated CD8-positive, alpha-beta T cell apoptotic process |
GO_1900425 | Biological process | negative regulation of defense response to bacterium |
GO_0032700 | Biological process | negative regulation of interleukin-17 production |
GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
GO_0071641 | Biological process | negative regulation of macrophage inflammatory protein 1 alpha production |
GO_2000562 | Biological process | negative regulation of CD4-positive, alpha-beta T cell proliferation |
GO_0005739 | Cellular component | mitochondrion |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005737 | Cellular component | cytoplasm |
GO_0030145 | Molecular function | manganese ion binding |
GO_0004053 | Molecular function | arginase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ARG2 |
Protein name | Arginase-2, mitochondrial (EC 3.5.3.1) (Arginase II) (Kidney-type arginase) (Non-hepatic arginase) (Type II arginase) |
Synonyms | |
Description | FUNCTION: May play a role in the regulation of extra-urea cycle arginine metabolism and also in down-regulation of nitric oxide synthesis. Extrahepatic arginase functions to regulate L-arginine bioavailability to nitric oxid synthase (NOS). Arginine metabolism is a critical regulator of innate and adaptive immune responses. Seems to be involved in negative regulation of the survival capacity of activated CD4(+) and CD8(+) T cells . May suppress inflammation-related signaling in asthmatic airway epithelium . May contribute to the immune evasion of H.pylori by restricting M1 macrophage activation and polyamine metabolism (By similarity). In fetal dendritic cells may play a role in promoting immune suppression and T cell TNF-alpha production during gestation . Regulates RPS6KB1 signaling, which promotes endothelial cell senescence and inflammation and implicates NOS3/eNOS dysfunction . Can inhibit endothelial autophagy independently of its enzymatic activity implicating mTORC2 signaling . Involved in vascular smooth muscle cell senescence and apoptosis independently of its enzymatic activity . Since NOS is found in the penile corpus cavernosum smooth muscle, the clitoral corpus cavernosum and the vagina, arginase-2 plays a role in both male and female sexual arousal . . |
Accessions | P78540 ENST00000261783.4 |